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Neuro-immune alterations in the peripheral and central nervous system play a role in
the pathophysiology of chronic pain, and non-coding RNAs – and microRNAs (miRNAs)
in particular – regulate both immune and neuronal processes. Speciﬁcally, miRNAs
control macromolecular complexes in neurons, glia and immune cells and regulate signals
used for neuro-immune communication in the pain pathway. Therefore, miRNAs may be
hypothesized as critically important master switches modulating chronic pain. In particular,
understanding the concerted function of miRNA in the regulation of nociception and
endogenous analgesia and deﬁning the importance of miRNAs in the circuitries and
cognitive, emotional and behavioral components involved in pain is expected to shed new
light on the enigmatic pathophysiology of neuropathic pain, migraine and complex regional
pain syndrome. Speciﬁc miRNAs may evolve as new druggable molecular targets for pain
prevention and relief. Furthermore, predisposing miRNA expression patterns and inter-
individual variations and polymorphisms in miRNAs and/or their binding sites may serve
as biomarkers for pain and help to predict individual risks for certain types of pain and
responsiveness to analgesic drugs. miRNA-based diagnostics are expected to develop
into hands-on tools that allow better patient stratiﬁcation, improved mechanism-based
treatment, and targeted prevention strategies for high risk individuals.
Keywords: chronic pain, biomarker, polymorphism, miRNA-based diagnostics, miRNA expression patterns, miRNA
polymorphisms, antagomir, miRNA-based analgesic
INTRODUCTION
Human chronic pain disorders are bio-psycho-social diseases,
which are difﬁcult to treat due to their diversity. Chronic pain
syndromes that develop after nerve damage, trauma or surgery are
characterized by persistent and severe pain; they induce anxiety
and depression and greatly impair patients’ quality of life. One
out of ﬁve Europeans suffers from chronic pain with most report-
ing that they endure it for more than two years (Breivik et al.,
2006; Baker et al., 2010). Due to direct and follow-up costs they
constitute a heavy burden for the health system (Phillips, 2006).
Of the painful neuropathies, the most frequent, painful
diabetic polyneuropathy is a common complication of dia-
betes mellitus occurring in up to 20% of patients (Som-
mer, 2003; Sadosky et al., 2008). Good glycemic control can
reduce the incidence of diabetic polyneuropathy but not painful
diabetic polyneuropathy (PDPN) for which only symptomatic
therapy of low to moderate efﬁcacy is available to date
(Vincent et al., 2011). Cellular mechanisms are emerging that
include the classical changes of the diabetic milieu (Bierhaus and
Nawroth, 2012; Bierhaus et al., 2012) however various studies have
also identiﬁed signatures of neuroinﬂammation as critical com-
ponents of painful diabetic polyneuropathy (Pabreja et al., 2011;
Vincent et al., 2011). Pathological neuro-immune communication
has also been associated with painful neuropathy that occurs in up
to 50% of patients with traumatic peripheral nerve injury as a
consequence of accidents, warfare or surgical procedures (Myers
et al., 2006; Ciaramitaro et al., 2010; Birch et al., 2012). Also the
neurogenic complex regional pain syndrome (CRPS) occurring as
a complication of bone fracture, tissue injury or surgical interven-
tions has a neuro-inﬂammatory component (Parkitny et al., 2013).
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In the majority of cases symptoms grossly resolve, however in 30%
of patients pain symptoms persist or even intensify (Marinus et al.,
2011). The beneﬁcial effect of therapy with glucocorticosteroids
in the acute phase of CRPS supports pathophysiological mecha-
nisms associated with neuro-immune dysfunction (Üceyler et al.,
2007a; Fischer et al., 2010; Marinus et al., 2011). Thus, converging
evidence suggests that neuro-immune alterations in the periph-
eral and central nervous system play a major role in the general
pathophysiology of neurogenic and neuropathic pain (McMahon
and Malcangio, 2009; Kuner, 2010). Non-coding RNAs (ncRNAs),
including microRNAs (miRNAs) and Piwi-binding piRNAs, are
intimately associated with normal cellular as well as pathological
processes (Mattick, 2004; Hüttenhofer et al., 2005; Hüttenhofer
and Schattner, 2006). In this review we will focus on miRNAs
since they are most extensively studied so far.
Various diseases, including neuropathic pain disorders, reveal
unique miRNA expression signatures that can be exploited as
diagnostic and prognostic markers. Recent reports on miRNA
modulation of both neuronal and immune processes further
predict therapeutic potential for manipulating disease-modiﬁed
miRNAs in diseases affecting both the immune system and brain
function, such as neuropathic pain disorders, Alzheimer’s dis-
ease, Parkinson’s disease, multiple sclerosis, and anxiety-related
disorders (Soreq and Wolf, 2011; O’Connor et al., 2012).
miRNAs that functionwithinboth thenervous and the immune
systems possibly act as“negotiators”between these two interacting
compartments (Figure 1). These “neurimmiRs” primarily target
transcription factor genes or other regulatory genes, which enables
simultaneous modulation of both immune and neuronal pro-
cesses including cognition through direct or indirect alterations of
neuron–glia or brain-to-body signaling (Soreq and Wolf, 2011).
Thus, a given miRNA controls multiple cellular pathways, and
miRNAs can act as “master switches” of the transcriptome or
proteome, regulating multiple gene products and orchestrating
multiple pathways including genes that encode cellular enzymes,
trophic factors, receptor proteins, and ion channels many of which
are individually pursued as drug targets.
Pain conditions have been suggested to deregulate the expres-
sion of miRNAs in pain pathways from primary afferent noci-
ceptors to brain areas associated with emotional components of
FIGURE 1 |Targets of miRNA regulation networks.
pain perception (Bai et al., 2007; Aldrich et al., 2009; Kusuda et al.,
2011; Imai et al., 2011; Poh et al., 2011; von Schack et al., 2011).
miRNAs are frequently deregulated and expressed at aberrant lev-
els in diseased tissue, and ﬁrst evidence suggests that this applies
to neurogenic pain in CRPS (Orlova et al., 2011). Altered miRNA
expression is frequently a consequence of geneticmutations,which
may also cause loss or gain of function (Mishra andBertino, 2009).
This may account for inter-individual variation of pain sensitiv-
ity. However, the functional consequences of polymorphisms in
miRNA genes and/or their binding sites, the downstream targets
of miRNAs and the mechanisms by which miRNAs regulate cir-
cuitries and processes modulating nociception and endogenous
analgesia are as yet unresolved.
Therapeutic miRNA regulation has been thoroughly studied
and widely established in cancer research but its impact and the
therapeutic prospects of miRNAs in the pain ﬁeld are largely unex-
plored. Manipulation of miRNAs offers the possibility to control
multiple targets including neuro-immune interactions, nocicep-
tive processing and cognitive pathways. Both miRNAs and their
isomiRNA versions are likely to each interact with many different
targets, which may lead to downstream changes either due to the
direct suppression of these targets or because of regulatory effects
of those targets. Such downstream effects may be rather elaborate
and are deﬁned by some researchers “off-target” effects. However,
we ﬁnd that this deﬁnitionmay bemisleading as it assumes that the
physiological role of each miRNA is limited to the suppression of
its direct targets. It is expected that miRNAs and miRNA deriva-
tives will have few, if any, sequence-speciﬁc “off-target” effects.
Thus, miRNA based diagnostics and therapeutics may have supe-
rior advantages by targeting multiple pain-associated genes and
miRNA-based drugs may be the most appropriate therapy for the
prevention or treatment of neuropathic pain.
BIOMARKERS FOR NEUROPATHIC AND NEUROGENIC PAIN
SYNDROMES
Painful diabetic polyneuropathy is the most frequent painful neu-
ropathy occurring in up to 20% of diabetic patients (Sommer,
2003; Sadosky et al., 2008). CRPS is an extremely painful con-
dition that occurs in some patients after bone or tissue injury
and peripheral nerve injury (traumatic neuropathy) and results
in chronic neuropathic pain in many of these patients. These
well-characterized albeit aetiologically diverse (metabolic, inﬂam-
matory, traumatic) neuropathic/neurogenic pain syndromes cover
a spectrum of mechanisms underlying chronic pain. Nevertheless,
the medical need for these syndromes is prevalent, and each of
them is prototypic for an entire group of pain disorders.
It is unclear why diabetic neuropathy or traumatic neuropathy
are painful in some instances and painless in others or why some
patients develop CRPS after bone fracture, and why some recover
from CRPS and others do not (Marinus et al., 2011). Thus, as
yet unknown factors determine whether a given disorder entails
chronic neuropathic pain. A ﬁrst approach to be able to predict the
individual risk of pain chroniﬁcation was to use sensory pheno-
types as surrogate markers for possible underlying mechanisms.
Quantitative sensory testing (QST) is now well established but is
still insufﬁcient to disentangle speciﬁc pathophysiological mech-
anisms of chronic pain (Baron et al., 2012). One of the major
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hindrances in translating such ﬁndings into better therapy of
neuropathic and neurogenic pain syndromes is the complexity
of their pathophysiology. It is well known that alterations in many
processes including ion channels, inﬂammatory mediators, neu-
rotrophic factors, synaptic plasticity, and de- and regeneration, are
involved, and that they even change during the course of the dis-
ease (Hehn et al., 2012). Therefore, a search for better and more
speciﬁc diagnostic trait and state markers is one of the prerequi-
sites for successful treatment in the future. Circulating miRNAs
are detectable in body ﬂuids including blood and cerebrospinal
ﬂuid and may be useful as novel biomarkers amenable to clini-
cal diagnostic applications for various types of disease (Cogswell
et al., 2008; Orlova et al., 2011; Ajit, 2012; Weiland et al., 2012;
Machida et al., 2013). Therefore, it should be likewise promising
to carefully assess which circulating miRNAs and novel ncRNAs
are associated with neurogenic and neuropathic pain syndromes
and may emerge as reliable diagnostic biomarkers for painful dia-
betic polyneuropathy, nerve injury pain, CRPS, headache and
migraine.
NEW DRUGGABLE MOLECULAR TARGETS FOR PAIN
TREATMENT
Treatment of painful diabetic polyneuropathy is far from satisfac-
tory in many patients although this is the most intensely stud-
ied painful neuropathy in randomized controlled trials (RCTs).
National and international guidelines differ in their recommen-
dations about ﬁrst and second line treatment choices. While
pregabalin is favored by some (Bril et al., 2013), duloxetine or even
tricyclic antidepressants are ﬁrst choice in others (NICE-guideline;
Attal et al., 2010; Dworkin et al., 2007). All of these drugs have
adverse effects on diabetes. Furthermore, mean treatment effects
comprise only two points of pain reduction on a 11-point Likert
scale. In other types of neuropathy, like traumatic neuropathy or
the frequent inﬂammatory types, there is little or nodata at all from
RCTs on pain treatment. Even worse, treatment of CRPS is nei-
ther standardized, nor satisfactory, nor based onmulticentreRCTs.
From single center studies with very limited patient numbers some
evidence exists for anti-inﬂammatory treatment by corticosteroids
or bisphosphonates in acute but not chronic stages, and for behav-
ioral therapy for selected patients in chronic stages (de Tran et al.,
2010). For the most frequently used invasive treatment modali-
ties such as sympathetic blockers no RCT evidence of efﬁcacy is
available (Straube et al., 2010). Thus, more efﬁcacious and speciﬁc
medications are needed for both neurogenic and neuropathic pain
syndromes.
Both, the novel and speciﬁc mode of action and the ability
to function as master switches of entire signaling networks has
triggered enthusiasm for miRNAs as promising therapeutic tar-
gets although relatively little is known about the mechanisms of
cellular uptake, storage and mode of action of miRNA modula-
tors (van Rooji and Olson, 2012). In several rodent pain models,
deregulated expression of miRNAs was found in pain pathways
from primary afferent nociceptors to brain areas associated with
emotional components of pain perception (Figure 2; Bai et al.,
2007; Aldrich et al., 2009; Kusuda et al., 2011; Imai et al., 2011;
Poh et al., 2011; von Schack et al., 2011). First evidence sup-
porting a future for analgesic miRNA treatment comes from
FIGURE 2 | miRNA that may be causally associated with maintained
neuropathic pain in immune cells (Shaked et al., 2009; Soreq andWolf,
2011; Ponomarev et al., 2013), nociceptors/DRG (Zhao et al., 2010, 2013;
TamTam et al., 2011; Ni et al., 2012; Sakai and Suzuki, 2013), spinal cord
(Brandenburger et al., 2012; Favereaux et al., 2011; Im et al., 2012; Ni
et al., 2012;Willemen et al., 2012), insular cortex (Sanchez-Simon et al.,
2010), amygdala (Meerson et al., 2010; Haramati et al., 2011; Griggs
et al., 2013), prefrontal cortex (Poh et al., 2011), hippocampus (Edbauer
et al., 2010).
mice intrathecally receiving miR-124, miR-103 or miR-23b which
are reported to prevent and treat persistent inﬂammatory and
neuropathic pain (Favereaux et al., 2011; Imai et al., 2011; Wille-
men et al., 2012). Despite the fact that these miRNA treatments
reduced signatures of synaptic modiﬁcation, neuroinﬂammation
and microglial response, the full extent and the mechanisms of the
analgesic effect are not understood to date (Favereaux et al., 2011;
Willemen et al., 2012).
CIRCUITRIES AND PROCESSES MODULATING NOCICEPTION
AND ENDOGENOUS ANALGESIA
Various studies have identiﬁed signatures of neuroinﬂammation
as critical components of diabetic polyneuropathy (Pabreja et al.,
2011; Vincent et al., 2011) in addition to the cellular mecha-
nisms that include the classical changes of the diabetic milieu
(Bierhaus et al., 2012; Bierhaus and Nawroth, 2012). Patholog-
ical neuro-immune communication has been associated with
painful neuropathy following traumatic peripheral nerve injury
(Myers et al., 2006; Ciaramitaro et al., 2010; Birch et al., 2012).
Moreover, CRPS occurring as a complication of bone fracture
or tissue injury results from neurogenic inﬂammatory processes
(Goebel, 2011). In humans, a systemic pro-inﬂammatory pro-
ﬁle distinguishes painful from painless neuropathy, and a local
pro-inﬂammatory proﬁle is part of the pathophysiology of small
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ﬁber neuropathy (Üceyler et al., 2007b, 2010). Specialized periph-
eral neurons, the nociceptors sense inﬂammatory or neuropathic
conditions and respond with increased excitability and sensitivity
leading to persisting pain and hyperalgesia (Costigan and Woolf,
2000; Sommer and Kress, 2004; Berta et al., 2008; Üceyler et al.,
2009). However, mice lacking receptors for pro-inﬂammatory
mediators in their nociceptor neurons are frequently protected
from certain signatures of pathological pain (Andratsch et al.,
2009; Schweizerhof et al., 2009; Mair et al., 2011; Quarta et al.,
2011). The deﬁciency in anti-inﬂammatory cytokines in patients
with CRPS (Üceyler et al., 2007a) together with beneﬁcial effect
of therapy with glucocorticosteroids support pathophysiolog-
ical mechanisms associated with neuro-immune dysfunction
(Fischer et al., 2010).
Inﬂammatory processes are also activated in the spinal cord
upon peripheral nerve injury and involve microglia activation
and leakage at the blood nerve barrier along the entire neu-
raxis (McMahon and Malcangio, 2009; Beggs et al., 2010, 2012).
Microglia activation occurs in diabetic neuropathy in rodents
(Wodarski et al., 2009; Beggs et al., 2012; Talbot and Couture,
2012) and has been recognized to be critical for the maintenance
of neuropathic pain via the release of pro-nociceptive mediators
(Clark et al., 2007). Leakage of the blood nerve barrier or the blood
spinal barrier is just emerging in the pathophysiology of neuro-
pathic pain accompanied by changes in tight junction proteins
(Echeverry et al., 2011). Tight junctionproteinswhich are critically
involved in maintaining the blood–brain barrier like claudin-1 are
also new targets, e.g., of miR-155 (Qin et al., 2013).
Deregulated miRNAs can be a consequence or cause of local
inﬂammatory processes such as regulation of nociceptor sensi-
tisation by controlling phospholipase A2 activation (Sun et al.,
2012). Analyses of expression proﬁles of dorsal root ganglia (DRG)
containing nociceptor cell bodies reveal that particular miRNAs
are deregulated in rodent pain models giving rise to deregu-
lation of miRNA-targeted ion channel expression patterns and
metabotropic receptor transcripts in peripheral neurons which
presumably cause nociceptor dysfunction (Zhao et al., 2010; von
Schack et al., 2011). miRNAs are universal regulators of differen-
tiation, activation and polarization of microglia in normal and
inﬂammatory conditions (Ponomarev et al., 2013). Microglia and
macrophage activity is suppressed by speciﬁc miRNAs, e.g., miR-
124, and it is therefore anticipated that miRNA regulation is
critically involved in endogenous inhibition and resolution of
inﬂammation by e.g., resolvins (Ponomarev et al., 2011; Rec-
chiuti et al., 2011). Certain miRNAs are substantially suppressed
in glucocorticoid-treated thymocytes by reduced expression of the
keymiRNAprocessing enzymesDicer, Drosha, andDGCR8/Pasha
(Smith et al., 2010). This observation is of great relevance since
CRPS for example is regarded a prototype disorder of failed termi-
nation of inﬂammation (Birklein and Kingery, 2009). The spinal
release of immune modulators affects both spinal synaptic pro-
cesses and local inhibitory circuits, possibly by classical cytokine-
prostaglandin signaling and dys-inhibition of e.g., glycinergic
spinal control (Samad et al., 2001; Harvey et al., 2004). Plastic
changes at synapses in the spinal dorsal horn promote neuro-
pathic and neurogenic pain via mechanisms involving enhanced
nociceptive transmission but also inhibition of spinal endogenous
analgesic circuits (Hartmann et al., 2004;Harvey et al., 2004; Fossat
et al., 2007; Sandkühler, 2007, 2009; Pernía-Andrade et al., 2009;
Zeilhofer et al., 2009; Fossat et al., 2010; Laffray et al., 2012).
For a few miRNAs and long ncRNAs, downstream target
proteins have been reported. For example, a conserved long
ncRNA seems to modulate sensory neuron excitability by activa-
tion of a transcription factor MZF and downregulation of Kcna2
potassium channel expression and this has been causally associ-
ated with neuropathic pain (Zhao et al., 2013). In addition, the
functional consequences of miR-103 regulation of voltage-gated
Cav1.2 calcium channels and intrinsic excitability of spinal pro-
jection neurons have been demonstrated (Favereaux et al., 2011).
It is well accepted that certain hereditary forms of migraine are
associated with polymorphisms of voltage-gated calcium chan-
nels Cav2.1 and Cav2.2 (Pietrobon and Striessnig, 2003). Novel
evidence suggests that in particular endogenous pain control sys-
tems including GABAergic and opioidergic synaptic signals are
down-regulated by miRNAs such as miR-134 or miR-181a (Ni
et al., 2012; Sengupta et al., 2013). Some of them link miRNAs like
let-7 or miR-339 to opioid tolerance (He et al., 2010; He andWang,
2012;Wu et al., 2013). In analogy,miRNAneuronal dys-regulation
should not only apply to neurogenic or neuropathic pain but very
likely the same principles and pathways should apply to other pain
syndromes like headaches and in particular hereditary and other
forms of migraine.
COGNITIVE, EMOTIONAL AND BEHAVIORAL COMPONENTS
OF PAIN
Neuropsychological alterations are present in 65 % of CRPS
patients and in particular cognitive impairment and deﬁcits
of emotional decision-making may impact their quality of life
especially in risky, emotional situations (Apkarian et al., 2004).
Emotional deﬁcits and functional alterations in corresponding
brain regions are reported in chronic CRPS patients and pain-
related fear is one of the strongest predictors of disability in chronic
pain disorders (Geha et al., 2008; de Jong et al., 2011).
Speciﬁc areas in the brain are actively involved in pain per-
ception and behavior in humans and rodents and structural
brain changes are associated with sensory and emotional function
in rodent long-term neuropathic pain. In particular, decreased
volumes of primary somatosensory and frontal cortex, retrosple-
nial and entorhinal cortex, anterior cingulate cortex and insula
are maintained for months (Seminowicz et al., 2009). Specif-
ically, abnormalities in hippocampus volume are observed in
human CRPS and the mouse spared nerve injury (SNI) model.
Similar to CRPS patients, SNI mice show increased anxiety
like behavior and abnormal contextual fear extinction and this
is associated with reduced extracellular signal-regulated kinase
(ERK) expression, decreased neurogenesis and altered synaptic
plasticity (Kodama et al., 2007; Mutso et al., 2012). Mice with
experimental neuropathic pain also show cognitive deﬁcits in
novel object recognition and this is associated with deregulation
of glycinergic neurotransmission in the hippocampus (Kodama
et al., 2011), and may relate to reported enhanced quantal neu-
rotransmitter release in the anterior cingulate cortex of mice
with neuropathic pain (Toyoda et al., 2009). Dopaminergic and
glutamatergic inputs from amygdala, hippocampus and prefrontal
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cortex to the nucleus accumbens participate in the putative emo-
tional control circuits and recent human brain activity studies
have examined the nucleus accumbens in the emotional aspects
of pain processing (Baliki et al., 2010). These reports further
link chronic pain with emotional dysfunction, and maladaptive
responses of the nucleus accumbens in neuropathic pain have
recently been associated with deregulated miRNAs in this region
(Imai et al., 2011).
Brain-speciﬁc miRNAs are emerging as regulators of cogni-
tion, neuronal plasticity and memory by manipulating synapse
structure and function, and speciﬁc miRNAs not only control
cognition and emotional processes but also neuro-immune com-
munication in the brain (Bredy et al., 2011; Soreq andWolf, 2011).
Mental retardation has been associated with miR-125b, miR-132
and other miRNAs and this arises from effects on dendritic spine
morphology and synaptic physiology at hippocampal neurons.
AMPA-mediated miniature mEPSC amplitude and frequency are
reduced by neuronal over-expression of miR-125b and increased
by miR-132 and this is due to differential regulation of gluta-
mate NR2A and NR2B receptor mRNA levels (Edbauer et al.,
2010). Other glutamate receptor subunits in the brain are reg-
ulated by dopamine through miR-181a which has recently been
associated with the pain system (Saba et al., 2012). miR-132 is a
highly interesting brain speciﬁc miRNA since it is up-regulated
by brain derived neurotrophic factor (BDNF) and other growth
factors in cortical neurons and this results in an increased expres-
sion of synaptic proteins including glutamate receptors (NR2A,
NR2B and GluA1), an effect that is attenuated by glucocorticoids
(Kawashima et al., 2010; Numakawa et al., 2011). Hippocam-
pal miR-132 mediates stress-inducible cognitive deﬁcits through
acetylcholinesterase as a downstream target and speciﬁcally in
the amygdala miR-34 is associated with the repression of stress-
induced anxiety (Haramati et al., 2011; Shaltiel et al., 2013). More
generally, happiness, anxiety and depression seem to depend on
miRNA expression levels. Speciﬁc miRNAs are deregulated in
patients suffering from depression and anxiety, and in pre-clinical
models of psychological stress (Meerson et al., 2010). Moreover,
psychoactive agents, including antidepressants and mood stabi-
lizers, utilize miRNAs as downstream effectors (O’Connor et al.,
2012). This further links neuropathic pain to emotional disorders
and to the clinical beneﬁt of antidepressants for pain treatment
(Dworkin et al., 2007).
PAIN PREDISPOSING GENETIC POLYMORPHISMS
There is evidence that chronic pain, pain sensitivity and respon-
siveness to analgesic opioids show a sufﬁcient heritability to make
these phenotypes highly interesting sources for genetic variabil-
ity which has an inﬂuence on pain (Angst et al., 2012; Hocking
et al., 2012; Nielsen et al., 2012). Altered miRNA expression is fre-
quently a consequence of genetic mutations, which may also cause
loss or gain of function (Mishra and Bertino, 2009). This may
account for signiﬁcant inter-individual variation in the response
to painful stimuli and analgesic drugs. Polymorphisms of speciﬁc
molecular targets may be associated with certain pain phenotypes
and this has emerged for example for a speciﬁc calcium chan-
nel subunit in a Drosophila screen that is conserved in mice and
humans (Mogil, 2012; Neely et al., 2010). Several meta-analyses
are available of the genetics of pain and associated speciﬁc loss-
or gain of function polymorphisms with altered pain perception
(LaCroix-Fralish et al., 2011; Mogil, 2012). A recent genome-wide
association (GWA) study revealed three susceptibility loci for com-
mon migraine in the general population, however, systematic
association studies are unavailable for DPN and CRPS to date
(Chasman et al., 2011). In general, genetic studies have helped to
understand the role and downstream mechanisms of individual
proteins in pain processing, but speciﬁc single nucleotide poly-
morphism (SNP) related pain disorders apply to small numbers
of individuals only and so far do not explain the large vari-
ability regarding susceptibility to distinct pain disorders or the
responsiveness todifferent pain therapies in the general population
(Dworkin et al., 2007; Attal et al., 2010).
The functional consequences of polymorphisms in miRNA
genes and/or their binding sites, the downstream targets of miR-
NAs and the mechanisms by which miRNAs regulate circuitries
and processes modulating nociception and endogenous analgesia
are entirely unaddressed. SNPs in miRNAs or their target sites
are not only bioinformatically predicted to be associated with the
pathogenesis of diseases but are also experimentally validated (Wu
et al., 2008; Coassin et al., 2010). It is known that SNPs are less
common in miRNAs or their target sites than in other parts of the
genome which points to the importance of miRNAs for cellular
processes. However, on the other handSNPs in these sites can affect
the expression of a large number of genes when the production of
themiRNA is inﬂuenced by that particular SNP.Moreover, SNPs in
target sites of miRNAs can either modulate/disrupt existing bind-
ing sites or create new binding sites for the miRNAs that may then
inﬂuence gene expression. SNPs in these regions have become a
major focus of research and some of them are expected to explain
pathogenetic mechanisms in disease development (Glinsky, 2008;
Haas et al., 2012). For example, miRNA expression is markedly
different between normal tissues and tumor tissues although oth-
erwise miRNA expression is strictly controlled. This might be
explained by somatic mutations that are introduced during car-
cinogenesis. The investigation of genetic variants at miRNAs or
their target sites and their association with various diseases is only
in its infancy. Initial studies show that these RNA chainsmight also
be involved in neurological diseases such as Parkinson’s disease
(Martins et al., 2011), Alzheimer’s disease (Serpente et al., 2011)
or frontotemporal lobar degeneration (Villa et al., 2011). The
identiﬁcation of SNPs in miRNA related regions of the genome
might be advantageous over classical GWA study since individual
ncRNAs may control and regulate whole networks and pathways
involving a multitude of functional proteins. This may open a
new avenue that may potentially improve our understanding of
extensive inter-individual differences in patients.
TRANSLATION OF PRE-CLINICAL AND CLINICAL RESULTS
INTO SOLUTIONS FOR THE BENEFIT OF PATIENTS
As stated above, one of the major hindrances in the way of
translating such ﬁndings into better therapy of neuropathic and
neurogenic pain syndromes is the complexity of their patho-
physiology, which even changes during the course of disease.
Based on and in analogy to recent developments in the oncology
ﬁeld, an improved understanding of the role of miRNAs in
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neuropathic pain might be highly useful for diagnostic and prog-
nostic assessments. For example, aberrant expression or functional
deregulation of miRNAs has been associated with the risk for
and progression of malignancies and this knowledge is expected
to advance the management of certain cancer types through the
development of novel personalized miRNA-based diagnostics and
therapies (Dreussi et al., 2012; Rossi and Calin, 2013). Increas-
ing evidence indicates that certain miRNAs may be aberrantly
expressed or deregulated in certain individuals after tissue injury
orwith diabetes. Thismay be associatedwith increased risk of pain
chroniﬁcation or even responsiveness to analgesic drugs (Ivanov
et al., 2012). Therefore, miRNAs are expected to have potential
for personalized pain medicine as biomarkers for risk assessment,
drug selection and novel therapies.
Therapeutic miRNA regulation has been thoroughly studied
and begins to be established in different types of cancer, and
the ﬁrst miRNA targeted drug has entered phase II clinical trials
(Lindow and Kauppinen, 2012). In contrast, the potential ther-
apeutic impact of miRNAs in the pain ﬁeld is as yet largely
unexplored. To date, therapeutic approaches have been restricted
to rodent models and intrathecal administration and some incon-
sistencies have emerged; thus miRNA increases in a disease may be
either a cause or a feedback reaction to theobserved symptoms. For
example, although miR-124 is up-regulated after chronic constric-
tive nerve injury (CCI), intrathecal administration of miR-124 can
prevent and treat persistent inﬂammatory and neuropathic pain
(Willemen et al., 2012). Likewise, miR-132 levels are increased
in colon biopsies from patients with intestinal bowel disease
which should predictably limit inﬂammation (Maharshak et al.,
2013). Importantly,manipulation of miRNAs offers the possibility
to control multiple targets including neuro-immune interac-
tions, nociceptive processing and cognitive and affective pathways.
Thus, miRNA based therapeutics may have superior advantages
by targeting multiple pain-associated genes and miRNA-based
drugs may be the most appropriate therapy for the prevention or
treatment of neuropathic and neurogenic pain. At least, recent
developments provide an optimistic perspective on the evolu-
tion of therapeutic ncRNAs despite the drawback of unresolved
obstacles for successful delivery and unknown, however unlikely,
off-target effects (Cho, 2012).
Manipulating miRNAs as a therapeutic tool presents signiﬁ-
cant theoretical and practical challenges that must be overcome
before this approach becomes a reality. Speciﬁc examples involve
two of the more straightforward approaches for miRNA modula-
tion, miRNA mimics and antagomirs (Figure 3). miRNA mimics
consist of over-expressing speciﬁc miRNAs that are reduced in the
disease state. This mimic approach could be done by introduc-
ing synthetic oligonucleotides (natural or modiﬁed) or involve
over-expression of such miRNAs from an introduced viral vec-
tor. Antagomirs are synthetic oligonucleotide sequences that are
designed to be inversely oriented (antisense) to miRNAs that
are over-expressed in the disease state and which can form
Watson-Crick base pairing with the target miRNA. This can either
inactivate a miRNA or result in its degradation. Similar to the
miRNA mimics, these therapeutic and research tools can also
consist of synthetic or modiﬁed nucleic acid sequences or be
overexpressed from viral vectors.
Alternative methodologies used in experimental settings
include miRNA sponges, which are exogenous DNA repeats of
the target sequence and can serve to soak up excess copies of the
excess miRNA (Ebert et al., 2007). The miRNA sponges may be
produced under the regulation of RNA Polymerase III promot-
ers and can generate high amounts of speciﬁc target sequences.
Another novel yet promising approach involves target protection.
In this application, modiﬁed antisense oligonucleotides such as
LNA or morpholinos are prepared that will be complementary
to a speciﬁc sequence in the target gene messenger RNA. These
are added to the cells, where they bind to the target sequence,
block its down-regulationby themiRNAcomplex and ensure sufﬁ-
cient expression of the target mRNA (Choi et al., 2007). Enhanced
and prolonged miRNA suppression and simultaneous targeting of
multiple miRNAs can be achieved by inhibitors carrying clustered
hairpins based on the “Tough decoy” (TuD) design which offer
the advantage of standardized suppression of families or clusters
of miRNAs and can be combined with recombinant adenovirus
vectors (Haraguchi et al., 2009; Xie et al., 2012; Bak et al., 2013;
Hollensen et al., 2013).
An important difﬁculty that may be predicted for developing
neuronal miRNA therapeutics is delivery, since targeting to the
brain involves the signiﬁcant hurdle of crossing the blood–brain
barrier. Nevertheless, therapeutic efﬁcacy of certain approaches
such as the use of LNA antagomirs has been demonstrated even
in primate models, and certain neuronal miRNA therapeutic
approaches are now in preclinical development. These studies
cover several creative approaches that have been developed to
overcome the delivery problem. Thus, ∼20-mer miRNA-size
oligonucleotides are indeed unlikely to cross the blood–brain
barrier. However, peripheral administration of oligonucleotide
controllers of inﬂammation-regulatingmiRNAswould change the
levels of cytokines, and cytokines can penetrate and affect the
brain. Such effects have been demonstrated for miR-132 (Shaked
et al., 2009) and miR-212 (Hollander et al., 2010). Other means
include direct infection of cerebral neurons with viral vectors that
may be adapted for better tropism to neuronal cells (Barbash et al.,
2013). Direct introduction of antisense oligonucleotides can alter-
natively be performed by intracerebroventricular or local stereo-
tactic injection though these would be extremely problematic in
pain syndromes. Yet more recent work described the use of rabies
virus glycoprotein labeled nanoparticles to enable direct delivery
of a miRNA mimic to neuronal cells (Hwang do et al., 2011).
CONCLUSION
Recently, speciﬁc miRNAs have been associated with patho-
logical pain and the deregulation of ion channel expression
in sensory neurons in rodent pain models (Zhao et al., 2010;
Favereaux et al., 2011; Li et al., 2011). Pain conditions have
been suggested to deregulate the expression of miRNAs in
pain pathways from primary afferent nociceptors to brain
areas associated with emotional components of pain percep-
tion (Bai et al., 2007; Aldrich et al., 2009; Imai et al., 2011;
Kusuda et al., 2011; Poh et al., 2011; von Schack et al., 2011;
Arai et al., 2013; Genda et al., 2013; Sakai and Suzuki, 2013).
Unique signatures of miRNAs are associated with altered innate
immune signaling and secreted miRNAs are even considered
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FIGURE 3 | Endogenous miRNAs are generated from primary (pri-)
miRNAs via cleavage by the RNAse Drosha into pre-miRNAs in the
nucleus. They are exported into the cytosol by Exportin 5 and there are
cleaved into active miRNAs by the RNAse Dicer. Depending on the
degree of homology, miRNAs trigger translational repression or
degradation of target mRNAs (for review see He and Hannon, 2004;
Bartel, 2009). Therapeutic manipulations of miRNAs may involve various
methods. Host tissue miRNAs (gray) bind to complementary sequences,
which are often located in the 3′-untranslated region (3′-UTR) of the
target genes. This leads to translational repression, often accompanied by
degradation. Mimicking this process, miRNA mimics (green) with similar
sequences to those of miRNAs may be designed to target the same
mRNAs. Such mimics are synthetic oligonucleotides that are chemically
protected against nucleolytic degradation. Alternative routes include
molecular “sponges,” with several binding sites of a certain miRNA;
antagomiRs (red), complementary oligonucleotides to the host miRNA
which bind to it and limit its function, and target masks, which bind to
part of target miRNAs and compete with their function. Thus, tools exist
both for inducing gain of function (red arrows) or loss of function (dashed
blue arrows).
anew formof neuroimmune communication and control immune
cell activity as well as neuron function (Peng et al., 2010; Bredy
et al., 2011; Chen et al., 2012; Ponomarev et al., 2013). miRNAs
act at the neuro-immune interface which controls neuronal plas-
ticity and memory but also are linked to the etiology of anxiety
and mood disorders (Bredy et al., 2011; Soreq and Wolf, 2011;
O’Connor et al., 2012; Shaltiel et al., 2013). Such deﬁcits in the
interaction of immune cells and neurons together with cognitive
and emotional alterations in patients with neuropathic or neu-
rogenic pain syndromes are hypothesized to converge on miRNA
deregulated mechanisms along the entire neuraxis, and alterations
in miRNA expression may account for the variation of suscep-
tibility to certain types of pain or even for the responsiveness to
analgesics and opioid tolerance (Parsons et al., 2008). Understand-
ing the role of miRNAs in painmechanisms is suggested to provide
great beneﬁt for clinical diagnostic and therapeutic applications.
ACKNOWLEDGMENTS
This work is supported by the European Commission (GA N
602133 - ncRNAPain).
REFERENCES
Ajit, S. K. (2012). Circulating
microRNAs as biomarkers, therapeu-
tic targets, and signaling molecules.
Sensors (Basel) 12, 3359–3369. doi:
10.3390/s120303359
Aldrich, B. T., Frakes, E. P., Kasuya,
J., Hammond, D. L., and Kitamoto,
T. (2009). Changes in expression of
sensory organ-speciﬁc microRNAs in
rat dorsal root ganglia in association
with mechanical hypersensitivity
induced by spinal nerve ligation.
Neuroscience 164, 711–723. doi:
10.1016/j.neuroscience.2009.08.033
Andratsch, M., Mair, N., Constantin,
C. E., Scherbakov, N., Benetti, C.,
Quarta, S., et al. (2009). A key role
for gp130 expressed on peripheral
sensory nerves in pathological pain.
J. Neurosci. 29, 13473–13483. doi:
10.1523/JNEUROSCI.1822-09.2009
Angst, M. S., Phillips, N. G., Drover,
D. R., Tingl, M., Ray, A., Swan,
G. E., et al. (2012). Pain sensitivity
and opioid analgesia: a pharmacoge-
nomic twin study. Pain 153, 1397–
1409. doi: 10.1016/j.pain.2012.02.
022
Apkarian, A. V., Sossa, Y., Krauss,
B. R., Thomas, P. S., Fredrick-
son, B. E., Levy, R. E., et al.
(2004). Chronic pain patients are
impaired on an emotional decision-
making task. Pain 108, 129–136. doi:
10.1016/j.pain.2003.12.015
Arai, M., Genda, Y., Ishikawa, M.,
Shunsuke, T., Okabe, T., and
Sakamoto, A. (2013). The miRNA
and mRNA changes in rat hip-
pocampi after chronic constriction
injury. Pain Med. 14, 720–729. doi:
10.1111/pme.12066
Attal, N., Cruccu, G., Baron, R., Haan-
pää, M., Hansson, P., Jensen, T.
S., et al. (2010). EFNS guidelines
on the pharmacologcial treatment
of neuropathic pain. Eur. J. Neurol.
Frontiers in Molecular Neuroscience www.frontiersin.org October 2013 | Volume 6 | Article 33 | 7
“fnmol-06-00033” — 2013/10/17 — 13:25 — page 8 — #8
Kress et al. ncRNA in pain
17, 1113–e88. doi: 10.1111/j.1468-
1331.2010.02999.x
Bai, G., Ambalavanar, R., Wei, D.,
and Dessem, D. (2007). Downreg-
ulation of selective microRNAs in
trigeminal ganglion neurons follow-
ing inﬂammatory muscle pain. Mol.
Pain 3, 15. doi: 10.1186/1744-8069-
3-15
Bak, R. O., Hollensen, A. K., Primo,
M. N., Sørensen, C. D., and
Mikkelsen, J. G. (2013). Potent
microRNA suppression by RNA
Pol II-transcribed ‘Tough Decoy’
inhibitors. RNA 19, 280–293 doi:
10.1261/rna.034850.112
Baker, M., Collet, B., Fischer, A., Her-
mann, V., Huygen, F. J. P., Trueman,
P., et al. (2010). Improving the Current
and Future Management of Chronic
Pain. A European Consensus Report.
Brussels: Pﬁzer.
Baliki, M. N., Geha, P. Y., Fields, H.
L., and Apkarian, A. V. (2010). Pre-
dicting value of pain and analgesia:
nucleus accumbens response to nox-
ious stimuli changes in the presence
of chronic pain. Neuron 66, 149–160.
doi: 10.1016/j.neuron.2010.03.002
Barbash, S., Hanin, G., and Soreq,
H. (2013). Stereotactic injection of
microRNA-expressing lentiviruses to
the mouse hippocampus CA1 region
and assessment of the behavioral out-
come. J. Vis. Exp. doi: 10.3791/
50170
Baron, R., Forster, M., and Binder,
A. (2012). Subgrouping of patients
with neuropathic pain according
to pain-related sensory abnormal-
ities: a ﬁrst step to a stratiﬁed
treatment approach. Lancet Neurol.
11, 999–1005. doi: 10.1016/S1474-
4422(12)70189-8
Bartel, D. P. (2009). MicroRNAs: tar-
get recognition and regulatory func-
tions. Cell 136, 2015–2233 doi:
10.1016/j.cell.2009.01.002
Beggs, S., Liu, X. J., Kwan, C., and
Salter,M.W. (2010). Peripheral nerve
injury and TRPV1-expressing pri-
mary afferent C-ﬁbres cause open-
ing of hte blood–brain barrier. Mol.
Pain 6, 74. doi: 10.1186/1744-8069-
6–74.
Beggs, S., Trang, T., and Salter, M.
W. (2012). P2X4R(+)microglia drive
neuropathic pain. Nat. Neurosci. 15,
1068–1073. doi: 10.1038/nn.3155
Berta, T., Poirot, O., Pertin, M., Ji,
R. R., Kellenberger, S., and Decos-
terd, I. (2008). Transcriptional and
functional proﬁles of voltage-gated
Na+ channels in injured and non-
injured DRG neurons in the SNI
model of neuropathic pain. Mol.
Cell. Neurosci. 37, 196–208. doi:
10.1016/j.mcn.2007.09.007
Bierhaus, A., Fleming, T., Stoyanov, S.,
Lefﬂer, A., Babes, A., Neacsu, C., et al.
(2012). Methylglyoxal modiﬁcation
of Na(v)1.8 facilitates nociceptive
neuron ﬁring and causes hyperal-
gesia in diabetic neuropathy. Nat.
Med. 18, 926–933. doi: 10.1038/
nm.2750
Bierhaus, A., and Nawroth, P. P. (2012).
Critical evaluation of mouse mod-
els used to study pain and loss of
pain perception in diabetic neuropa-
thy. Exp. Clin. Endocrinol. Diabetes
120, 188–190. doi: 10.1055/s-0032-
1304567
Birch, R., Misra, P., Stewart, M. P., Eard-
ley, W. G., Ramasamy, A., Brown,
K., et al. (2012). Nerve injuries sus-
tained during warfare: part I – epi-
demiology. J. Bone Joint Surg. Br.
94, 523–528. doi: 10.1302/0301-
620X.94B4.28483
Birklein, F., and Kingery, W. S. (2009).
Complex regional pain syndrome: a
loss of inhibition? Pain 142, 177–178.
doi: 10.1016/j.pain.2009.01.029
Brandenburger, T., Castoldi, M., Bren-
del, M., Grievink, H., Schlösser,
L., Werdehausen, R., et al. (2012).
Expression of spinal cordmicroRNAs
in a rat model of chronic neuropathic
pain. Neurosci. Lett. 506, 281–286.
doi: 10.1016/j.neulet.2011.11.023
Bredy, T. W., Lin, Q., Wei, W., Baker-
Andresen, D., and Mattick, J. S.
(2011). MicroRNAregulationof neu-
ral plasticity and memory. Neuro-
biol. Learn. Mem. 96, 89–94. doi:
10.1016/j.nlm.2011.04.004
Breivik, H., Collett, B., Ventafridda,
V., Cohen, R., and Gallacher, D.
(2006). Survey of chronic pain in
Europe: prevalence, impact on daily
life, and treatment. Eur. J. Pain 10,
287–333. doi: 10.1016/j.ejpain.2005.
06.009
Bril, V., England, J., Franklin, G. M.,
Backonja, M., Cohen, J., Del Toro,
D., et al. (2013). Evidence-based
guidelines: treatment of painful dia-
betic neuropathy: report of the
American Academy of Neurology,
the American Association of Neu-
romuscular and Electrodiagnostic
Medicine and theAmericanAcademy
of Physical Medicine and Rehabilita-
tion. Neurology 76, 1758–1765. doi:
10.1212/WNL.0b013e3182166ebe
Chasman, D. I., Schürks, M., Anttila, V.,
de Vries, B., Schminke, U., Launer,
L. J., et al. (2011). Genome-wide
association study reveals thress sus-
ceptibility loci for common migraine
in the general population. Nat. Genet.
43, 695–698. doi: 10.1038/ng.856
Cho, W. C. (2012). Exploiting the
therapeutic potential of microRNAs
in human cancer. Expert Opin.
Ther. Targets 16, 345–350. doi:
10.1517/14728222.2012.663354
Choi, W. Y., Giraldez, A. J., and
Schier, A. F. (2007). Target protectors
reveal dampening and balancing
of Nodal agonist and antago-
nist by miR-430. Science 318,
271–274. doi: 10.1126/science.114
7535
Ciaramitaro, P., Mondelli, M., Logullo,
F., Grimaldi, S., Battiston, B., Sard,
A., et al. (2010). Traumatic periph-
eral nerve injuries: epidemiologi-
cal ﬁndings, neuropathic pain and
quality of life in 158 patients. J.
Peripher. Nerv. Syst. 15, 120–127. doi:
10.1111/j.1529-8027.2010.00260.x
Clark, A. K., Yip, P. K., Grist, J.,
Gentry, C., Staniland, A. A., Marc-
hand, F., et al. (2007). Inhibition of
spinal microglial cathepsin S for the
reversal of neuropathic pain. Proc.
Natl. Acad. Sci. U.S.A. 104, 10655–
10660. doi: 10.1073/pnas.061081
1104
Coassin, S., Brandstätter, A., and Kro-
nenberg, F. (2010). Lost in the space
of bioinformatic tools: a constantly
updated survival guide for genetic
epidemiology. The GenEpi Toolbox.
Atherosclerosis 209, 321–335. doi:
10.1016/j.atherosclerosis.2009.10.026
Cogswell, J. P., Ward, J., Taylor, I. A.,
Waters, M., Shi, Y., Cannon, B.,
et al. (2008). Identiﬁcation of miRNA
changes in Alzheimer’s disease brain
and CSF yields putative biomarkers
and insights into disease pathways.
Alzheimers Dis. 14, 27–41.
Costigan, M., and Woolf, C. J. (2000).
Pain: molecular mechanisms. J. Pain
3, 35–44. doi: 10.1054/jpai.2000.9818
de Jong, J. R., Vlaeyen, J. W., de Gelder,
J. M., and Patijn, J. (2011). Pain-
related fear, perceived harmfulness of
activities, and functional limitations
in complex regional pain syndrome
type I. J. Pain 12, 1209–1218. doi:
10.1016/j.jpain.2011.06.010
de Tran, Q. H., Duon, G., Bertini, P.,
and Finlayson, R. J. (2010). Treat-
ment of complex regional pain syn-
drome: a review of the evidence.
Can. J. Anaesth. 57, 149–166. doi:
10.1007/s12630-009-9237-0
Dreussi, E., Biason, P., Toffoli, G.,
and Ceccin, E. (2012). miRNA
pharmacogenomics: the new frontier
for personalized medicine in cancer?
Pharmacogenomics 13, 1635–1650.
doi: 10.2217/pgs.12.147
Dworkin, R. H., O’Connor, A. B., Back-
onja, M., Farrar, J. T., Finnerup,
N. B., Jensen, T. S., et al. (2007).
Pharmacological management of
neuropathic pain: evidence-based
recommendations. Pain 132, 237–
251. doi: 10.1016/j.pain.2007.08.033
Ebert, M. S., Neilson, J. R., and Sharp, P.
A. (2007). MicroRNA sponges: com-
petitive inhibitors of small RNAs in
mammalian cells. Nat. Methods 4,
721–726. doi: 10.1038/nmeth1079
Echeverry, S., Shi, X. Q., Rivest, S.,
and Zhang, J. (2011). Peripheral
nerve injury alters blood-spinal
cord barrier functional and molec-
ular integrity through a selective
inﬂammatory pathway. J. Neu-
rosci. 31, 10819–10828. doi:
10.1523/JNEUROSCI.1642-11.2011
Edbauer, D., Neilson, J. R., Fos-
ter, K. A., Wang, C.-F., See-
burg, D. P., Batterton, M. N.,
et al. (2010). Regulation of synaptic
structure and function by FMRP-
associated microRNAs miR-125b and
miR-132. Neuron 65, 373–384. doi:
10.1016/j.neuron.2010.01.005
Favereaux, A., Thoumine, O., Bouali-
Benazzouz, R., Roques, V., Papon,
M. A., Salam, S. A., et al. (2011).
Bidirectional integrative regulation
of Cav1.2 calcium channel by
microRNA miR-103: role in pain.
EMBO J. 30, 3830–3841. doi:
10.1038/emboj.2011.249
Fischer, S. G. L., Zuumond, W. W. A.,
Birklein, F., Loer, S. A., and Perez, R.
S. G. M. (2010). Anti-inﬂammatory
treatment of complex regional pain
syndrome. Pain 151, 251–256. doi:
10.1016/j.pain.2010.07.020
Fossat, P., Dobremez, E., Bouali-
Benazzouz, R., Favereaux, A.,
Bertrand, S., Kilk, K., et al.
(2010). Knock-down of L cal-
cium channel subtypes: differen-
tial effects on neuropathic pain.
J. Neurosci. 30, 1073–1085. doi:
10.1523/JNEUROSCI.3145-09.2010
Fossat, P., Sibon, I., LeMasson, G.,
Landry, M., and Nagy, F. (2007). L-
type calcium channels and NMDA
receptors: a determinant duo for
short-termnociceptive plasticity. Eur.
J. Neurosci. 25, 127–135. doi:
10.1111/j.1460-9568.2006.05256.x
Geha, P. Y., Baliki, M. N., Harden,
R. N., Bauer, W. R., Parrish, T.
B., and Apkarian, A. V. (2008).
The brain in chronic CRPS pain:
abnormal gray-white matter interac-
tions in emotional and authnomic
regions. Neuron 60, 570–581. doi:
10.1016/j.neuron.2008.08.022
Genda, Y., Arai, M., Ishikawa, M.,
Tanaka, S., Okabe, T., and Sakamoto,
A. (2013). microRNA changes in the
dorsal horn of the spinal cord of rats
with chronic constriction injury: A
TaqMan® Low Density Array study.
Int. J. Mol. Med. 31, 129–137. doi:
10.3892/ijmm.2012.1163
Glinsky, G. V. (2008). An SNP-guided
microRNA map of ﬁfteen common
Frontiers in Molecular Neuroscience www.frontiersin.org October 2013 | Volume 6 | Article 33 | 8
“fnmol-06-00033” — 2013/10/17 — 13:25 — page 9 — #9
Kress et al. ncRNA in pain
human disorders identiﬁes a con-
sensus disease phenocode aiming at
prinicpal components of the nuclear
import pathway. Cell Cycle 7, 2570–
2583. doi: 10.4161/cc.7.16.6524
Goebel, A. (2011). Complex regional
pain syndrome in adults. Rheuma-
tology 50, 1739–1750. doi:
10.1093/rheumatology/ker202
Griggs, E. M., Young, E. J., Rum-
baugh, G., and Miller, C. A. (2013).
MicroRNA-182 regulates amygdala-
dependent memory formation. J.
Neurosci. 33, 1734–1740. doi:
10.1523/JNEUROSCI.2873-12.2013
Haas, U., Sczakiel, G., and Laufer, S.
D. (2012). MicroRNA-mediated reg-
ulation of gene expression is affected
by disease-asssociated SNPs within
the 3’UTR via altered RNA struc-
ture. RNA Biol. 9, 924–937. doi:
10.4161/rna.20497
Haraguchi, T., Ozaki, Y., and
Iba, H. (2009). Vectors express-
ing efﬁcient RNA decoys achieve
the long-term suppression of speciﬁc
microRNA activity in mammalian
cells. Nucleic Acid Res. 37, e43. doi:
10.1093/nar/gkp040
Haramati, S., Navon, I., Issler, O.,
Ezra-Nevo, G., Gil, S., Zwang,
R., et al. (2011). microRNAs as
repressors of stress-induced anxi-
ety: the case of amygdalar miR-34.
J. Neurosci. 31, 14191–14203. doi:
10.1523/JNEUROSCI.1673-11.2011
Hartmann, B., Ahmadi, S., Heppen-
stall, P. A., Lewin, G. R., Schott,
C., Borchardt, T., et al. (2004).
The AMPA receptor subunits GluR-
A and GluR-B reciprocally modu-
late spinal synaptic plasticity and
inﬂammatory pain. Neuron 44, 637–
650. doi: 10.1016/j.neuron.2004.
10.029
Harvey, R. J., Depner, U. B., Wassle, H.,
Ahmadi, S., Heindl, C., Reinold, H.,
et al. (2004). GlyR alpha3: an essen-
tial target for spinal PGE2-mediated
inﬂammatory pain sensitization. Sci-
ence 304, 884–887. doi: 10.1126/sci-
ence.1094925
He, L., and Hannon, G. J. (2004).
MicroRNAs: small RNAs with a big
role in gene regulation. Nat. Rev.
Genet. 5, 522–531. doi: 10.1038/nrg
1379
He, Y., and Wang, Z. J. (2012). Let-
7 microRNAs and opoid tolerance.
Front. Genet. 3:110 doi: 10.3389/
fgene.2012.000110
He, Y., Yang, C., Kirkmire, C. M.,
and Wang, Z. J. (2010). Regula-
tion of opoid tolerace by let-7 family
microRNA targeting the mu opioid
receptor. J. Neurosci. 30, 10251–
10258. doi: 10.1523/JNEUROSCI.
2419-10.2010
Hehn, C. A., Baron, R., and Woolf, C.
J. (2012). Deconstructing the neu-
ropathic pain phenotype to reveal
neural mechanisms. Neuron 73, 638–
652. doi: 10.1016/j.neuron.2012.02.
008
Hocking, L. J., Generation, S., Mor-
ris, A. D., Dominiczak, A. F., Por-
teous, D. J., and Smith, B. H.
(2012). Heritability of chronic pain
in 2195 extended families. Eur. J. Pain
16, 1053–1063. doi: 10.1002/j.1532-
2149.2011.00095.x
Hollander, J. A., Im, H. I., Amelio,
A. L., Kocerha, J., Bali, P., Lu, Q.,
et al. (2010). Striatal microRNA con-
trols cocaine intake through CREB
signalling. Nature 466, 197–202. doi:
10.1038/nature09202
Hollensen, A. K., Bak, R. O., Haslund,
D., and Mikkelsen, J. G. (2013).
Suppression of microRNAs by dual
targeting and clustered Tough Decoy
inhibitors. RNA Biol. 10, 406–414.
doi: 10.4161/rna.23543
Hüttenhofer, A., and Schattner, P.
(2006). The principles of guid-
ing by RNA: chimeric RNA–protein
enzymes. Nat. Rev. Genet. 7, 475–482.
doi: 10.1038/nrg1855
Hüttenhofer, A., Schattner, P.,
and Polacek, N. (2005). Non-
coding RNAs: hope or hype?
Trends Genet. 21, 289–297. doi:
10.1016/j.tig.2005.03.007
Hwang do,W., Son, S., Jang, J.,Youn,H.,
Lee, S., Lee, D., et al. (2011). A brain-
targeted rabies virus glycoprotein-
disulﬁde linked PEI nanocarrier for
delivery of neurogenic microRNA.
Biomaterials 32, 4968–4975. doi:
10.1016/j.biomaterials.2011.03.047
Im,Y. B., Choi, J. I., Cho,H. T., Kwon,O.
H., and Kang, S. K. (2012). Molecular
targeting of NOX4 for neuropathic
pain after traumatic injury of the
spinal cord. Cell Death Dis. 3, e426.
doi: 10.1038/cddis.2012.168
Imai, S., Saeki, M., Yanase, M., Hori-
uchi, H., Abe, M., Narita, M.,
et al. (2011). Change in microR-
NAs associated with neuronal adap-
tive responses in the nucleus accum-
bens under neuropathic pain. J.
Neurosci. 31, 15294–15299. doi:
10.1523/JNEUROSCI.0921-11.2011
Ivanov, M., Kacevska, M., and
Ingelman-Sundberg, M. (2012).
Epigenomics and interindividual
differences in drug response. Clin.
Pharmacol. Ther. 92, 727–736. doi:
10.1038/clpt.2012.152
Kawashima, H., Numakawa, T., Kumu-
maru, E., Adachi, N., Mizuno,
H., Ninomiya, M., Kunugi, H.,
and Hashido, K. (2010). Gluco-
corticoid attenuates brain-derived
neurotrophic factor-dependent
upregulation of glutamate recep-
tors via the suppression of
microRNA-132 expression. Neu-
roscience 165, 1301–1311. doi:
10.1016/j.neuroscience.2009.11.057
Kodama, D., Ono, H., and Tan-
abe, M. (2007). Altered hippocampal
long-term potentiation after periph-
eral nerve injury in mice. Eur.
J. Pharmacol. 574, 127–132. doi:
10.1016/j.ejphar.2007.07.054
Kodama, D., Ono, H., and Tan-
abe, M. (2011). Increased hippocam-
pal glycine uptake and cognitive
dysfunction after peripheral nerve
injury. Pain 152, 809–817. doi:
10.1016/j.pain.2010.12.029
Kuner, R. (2010). Central mechanisms
fo pathological pain. Nat. Med.
16, 1258–1266. doi: 10.1038/nm.
2231
Kusuda, R., Cadetti, F., Ravanelli, M. I.,
Sousa, T.A., Zanon, S.,DeLucca, F. L.,
et al. (2011). Differential expression
of microRNAs inmouse painmodels.
Mol. Pain 7, 17. doi: 10.1186/1744-
8069-7–17
LaCroix-Fralish, M. L., Austin, J.-S.,
Zheng, F. Y., Levitin, D. J., and
Mogil, J. S. (2011). Patterns of pain:
meta-analysis of microarray studies
of pain. Pain 152, 1888–1898. doi:
10.1016/j.pain.2011.04.014
Laffray, S., Bouali-Benazzouz, R.,
Papon, M. A., Favereaux, A., Jiang,
Y., Holm, T., et al. (2012). Impair-
ment of GABAB receptor dimer by
endogenous 14-3-z in chronic pain
conditions. EMBO J. 31, 3239–3251.
doi: 10.1038/emboj.2012.161
Lindow, M., and Kauppinen, S. (2012).
Discovering the ﬁrst micrRNA-
targeted drug. J. Cell Biol. 199, 407–
412. doi: 10.1083/jcb.201208082
Machida, A., Ohkubo, T., and Yokota,
T. (2013). Circulating microR-
NAs in the cerebrospinal ﬂuid of
patients with brain diseases. Meth-
ods Mol. Biol. 1024, 203–209. doi:
10.1007/978-1-62703-453-1_16
Maharshak, N., Shenhar-Tsarfaty, S.,
Aroyo, N., Orpaz, N., Guber-
man, I., Canaani, J., et al. (2013).
Micro-RNA-132 modulates choliner-
gic signaling and inﬂammation in
human inﬂammatory bowel disease.
Inﬂamm. Bowel Dis. 19, 1346–
1353. doi: 10.1097/MIB.0b013e3182
81f47d
Mair, N., Benetti, C., Andratsch, M.,
Leitner, M. G., Constantin, C. E.,
Camprubí-Robles, M., et al. (2011).
Genetic evidence for involvement of
neuronally expressed S1P1receptor
in nociceptor sensitization and
inﬂammatory pain. PLoS ONE
6:e17268. doi: 10.1371/journal.pone.
0017268
Marinus, J., Moseley, G. L., Birklein,
F. B., Baron, R., Maihöfner, C.,
Kingery, W. S., et al. (2011). Clini-
cal features and pathophysiology of
complex regional pain syndrome.
Lancet Neurol. 10, 637–648. doi:
10.1016/S1474-4422(11)70106-5
Martins, M., Rosa, A., Guedes, L.
C., Fonseca, B. V., Gotovac, K.,
Violante, S., et al. (2011). Con-
vergence of miRNA expression pro-
ﬁling, a-synuclein interacton and
GWAS in Parkinson’s disease. PLoS
ONE 6:e25443. doi: 10.1371/jour-
nal.pone.0025443
Mattick, J. S. (2004). RNA regulation:
a new genetics? Nat. Rev. Genet. 5,
316–323. doi: 10.1038/nrg1321
McMahon, S. B., and Malcangio,
M. (2009). Current challenges in
glia-pain biology. Neuron 64, 46–54.
doi: 10.1016/j.neuron.2009.09.033
Meerson, A., Cacheaux, L., Goosens, K.
A., Sapolsky, R. M., Soreq, H., and
Kaufer, D. (2010). Changes in brain
microRNAs contribute to choliner-
gic stress reactions. J. Mol. Neurosci.
40, 47–55. doi: 10.1007/s12031-009-
9252-1
Mishra, P. J., and Bertino, J.
R. (2009). MicroRNA polymor-
phisms: the future of pharma-
cogenomics, molecular epidemiol-
ogy and individualized medicine.
Pharmacogenomics 10, 399–416. doi:
10.2217/14622416.10.3.399
Mogil, J. S. (2012). Pain genet-
ics: past, present and future.
Trends Genet. 28, 258–266. doi:
10.1016/j.tig.2012.02.004
Mutso, A. A., Radzicki, D., Baliki, M. N.,
Huang, L., Banisadr, G., Centeno, M.
V., et al. (2012). Abnormalities in hip-
pocampal functioningwithpersistent
pain. J. Neurosci. 32, 5747–5756. doi:
10.1523/JNEUROSCI.0587-12.2012
Myers, R. R., Campana, W. M., and
Shubayev, V. I. (2006) The role of
neuroinﬂammation in neuropathic
pain: mechanisms and therapeu-
tic targets. Drug Discov. Today 11,
8–20. doi: 10.1016/S1359-6446(05)
03637-8
Neely, G. G., Hess, A., Costigan, M.,
Keene, A. C., Goulas, S., Langes-
lag, M., et al. (2010). A genome-wide
Drosophila screen for heat nocicep-
tion identiﬁes a2d3 as evolutionarily
conserved pain gene. Cell 143, 628–
638. doi: 10.1016/j.cell.2010.09.047
Ni, J., Gao, Y., Gong, S., Guo,
S., Hisamitsu, T., and Jiang, X.
(2012). Regulation of m-opioid type
1 receptors my microRNA134 in dor-
sal root gnaglion neurons follow-
ing peripheral inﬂammation. Eur. J.
Pain doi: 10.1002/j.1532-2149.2012.
00197.x
Frontiers in Molecular Neuroscience www.frontiersin.org October 2013 | Volume 6 | Article 33 | 9
“fnmol-06-00033” — 2013/10/17 — 13:25 — page 10 — #10
Kress et al. ncRNA in pain
Nielsen, C. C., Knudsen, G. P.,
and Steingrimsdottir, O. A. (2012).
Twin studies of pain. Clin. Genet.
82, 331–340. doi: 10.1111/j.1399-
0004.2012.01938.x
Numakawa, T., Yamamoto, N., Chiba,
S., Richards, M., Ooshima, Y.,
Kishi, S., et al. (2011). Growth
factors stimulate expression of neu-
ronal and glial miR-132. Neu-
rosci. Lett. 505, 242–247. doi:
10.1016/j.neulet.2011.10.025
O’Connor, R. M., Dinan, T. G., and
Cryan, J. F. (2012). Little things on
which happiness depends: micrRNAs
as novel therapeutic targets for the
treatment of axiety and depression.
Mol. Psychiatry 17, 359–376. doi:
10.1038/mp.2011.162
Orlova, I. A., Alexander, G. M., Qureshi,
R. A., Sacan, A., Graziano, A., Bar-
ret, J. E., et al. (2011). MicroRNA
modulation in complex regional pain
syndrome. J. Transl. Med. 9, 195–204.
doi: 10.1186/1479-5876-9-195
Pabreja, K., Dua, K., Sharma, S.,
Padi, S. S. V., and Kulkarni, S. K.
(2011). Minocycline attenuates the
development of diabetic neuropathic
pain: possible anti-inﬂammatory
and anti-oxidant mechanisms. Eur.
J. Pharmacol. 661, 15–21. doi:
10.1016/j.ejphar.2011.04.014
Parkitny, L.,McAuley, J. H., Di Pietro, F.,
Stanton, T. R., O’Connell, N. E., Mar-
inus, J., et al. (2013). Inﬂammation
in complex regional pain syndrome:
a systematic review and meta-
analysis. Neurology 80, 106–117. doi:
10.1212/WNL.0b013e31827b1aa1
Parsons, M. J., Grimm, C. H., Paya-
Cano, J. L., Sugden, K., Nietfeld,
W., Lehrach, H., et al. (2008). Using
hippocampal microRNA expres-
sion diffeences between mouse
inbred strains to characterise miRNA
function. Mamm. Genome 19,
552–560. doi: 10.1007/s00335-008-
9116-y
Peng, X., Gralinski, L., Armour, C. D.,
Ferris, M. T., Thomas, M. J., and
Proll S., et al. (2010). Unique signa-
tures of long noncoding RNA expres-
sion in response to virus infection
and altered innated immune signal-
ing. mBio. 1, e00206–e00210. doi:
10.1128/mBio.00206-10
Pernía-Andrade, A. J., Kato, A., Witschi,
R., Nyilas, R., Katona, I., Freund, T.
F., et al. (2009). Spinal endocannabi-
noids and CB1 receptors mediate
C-ﬁber-induced heterosynaptic pain
sensitization. Science 325, 764. doi:
10.1126/science.1171870
Phillips, C. J. (2006). Economic burden
of chronic pain. Exp. Rev. Pharma-
coecon. Outcomes Res. 6, 591–601.
doi: 10.1586/14737167.6.5.591
Pietrobon, D., and Striessnig, J.
(2003). Neurobiology of migraine.
Nat. Rev. Neurosci. 4, 386–398. doi:
10.1038/nrn1102
Poh, K. W., Yeo, J. F., and Ong,
W. Y. (2011). MicroRNA changes
in the mouse prefrontal cortex after
inﬂammatory pain. Eur. J. Pain 801,
e1–e12.
Ponomarev, E. D., Veremeyko, T.,
Barteneva, N., Krichevsky, A. M., and
Weiner, H. L. (2011). MicroRNA-
124 promotes microglia quiescence
and suppresses EAE by deactivating
macrophages via the C/EPB-a-PU.1
pathway. Nat. Med. 17, 64–70. doi:
10.1038/nm.2266
Ponomarev, E. D., Veremeyko, T., and
Weiner, H. L. (2013). MicroRNAs
are universal regulators of differen-
tiation, activation, and polarization
of microglia and macrophages
in normal and diseased CNS.
Glia 61, 91–103. doi: 10.1002/
glia.22363
Qin, W., Ren, Q., Liu, T., Huang,
Y., and Wang, J. (2013). MicroRNA-
155 is a novel suppressor of ovarian
cancer-initiating cells that targets
CLDN1. FEBS Lett. 587, 1434–
1439. doi: 10.1016/j.febslet.2013.03.
023
Quarta, S., Vogl, C., Constantin, C. E.,
Üceyler, N., Sommer, C., and Kress,
M. (2011). Genetic evidence for an
essential role of neuronally expressed
IL-6 signal transducer gp130 in the
induction and maintenance of exper-
imentally induced mechanical hyper-
sensitivity in vivo and in vitro. Mol.
Pain 7, 73. doi: 10.1186/1744-8069-
7-73
Recchiuti, A., Krishnamoorthy, S., Fred-
man, G., Chiang, N., and Serhan,
C. N. (2011). MicroRNAs in resolu-
tion of acute inﬂammation: identiﬁ-
cation of novel resolvin D1-miRNA
circuits. FASEB J. 25, 544–560. doi:
10.1096/fj.10-169599
Rossi, S., and Calin, G. A. (2013). Bioin-
formatics, non-coding RNAs and
its possible application in personal-
ized medicine. Adv. Exp. Med. Biol.
774, 21–37. doi: 10.1007/978-94-007-
5590-1_2
Saba, R., Störchel, P. H., Aksoy-Aksel,
A., Kepura, F., Lippi, G., Plant, T.
D., et al. (2012). Dopamine-regulated
microRNA miR-181a controls GluA2
surface expression in hippocampal
neurons. Mol. Cell. Biol. 32, 619–632.
doi: 10.1128/MCB.05896-11
Sadosky, A., McDermott, A. M., Bran-
denburg, N. A., and Strauss, M.
(2008). A review of the epidemiology
of painful diabetic peripheral neu-
ropathy, postherpetic neuroalgia, and
less commonly studied neuropathic
pain conditions. Pain Pract. 8, 56. doi:
10.1111/j.1533-2500.2007.00164.x
Sakai, A., and Suzuki, H. (2013).
Nerve injury-induced upregulation
of miR-21 in the primary sensory
neurons contributes to neuropathic
pain in rats. Biochem. Biophys.
Res. Commun. 435, 176–181. doi:
10.1016/j.bbrc.2013.04.089
Samad, T. A., Moore, K. A., Sapirstein,
A., Billet, S., Allchorne, A., Poole,
S., et al. (2001). Interleukin-1b-
mediated induction of Cox-2 in the
CNS contributes to inﬂammatory
pain hypersensitivty. Nature 410,
471–475. doi: 10.1038/35068566
Sanchez-Simon, F. M., Zhang, X. X.,
Loh, H. H., Law, P. Y., and Rodriguez,
R. E. (2010). Morphine regulates
dopaminergic neuron differentiation
via miR-133b. Mol. Pharmacol. 78,
942. doi: 10.1124/mol.110.066837
Sandkühler, J. (2007). Understanding
LTP in pain pathways. Mol. Pain 3,
9. doi: 10.1186/1744-8069-3-9
Sandkühler, J. (2009). Models and
mechanisms of hyperalgesia and allo-
dynia. Physiol. Rev. 89, 707–758. doi:
10.1152/physrev.00025.2008
Schweizerhof, M., Stösser, S., Kurejova,
M., Njoo, C, Gangadharan, V., Agar-
wal, N., et al. (2009). Hematopoietic
colony-stimulating factors mediate
tumor-nerve interactions and bone
cancer pain. Nat. Med. 15, 802–807.
doi: 10.1038/nm.1976
Seminowicz, D. A., Laferriere, A.
L., Millecamps, M., Yu, J. S.
C., Codderre, T. J., and Bush-
nell, M. C. (2009). MRI structural
brain changes associated with sen-
sory and emotional function in a
rat model of long-term neuropathic
pain. Neuroimage 47, 1007–1014. doi:
10.1016/j.neuroimage.2009.05.068
Sengupta, J. N., Pochiraju, S.,
Kannampalli, P., Bruckert, M.,
Addya, S., Yadav, P., et al. (2013).
MicroRNA-mediatedGABA(Aalpha-
1) receptor subunit downregulation
in adult spinal cord follow-
ing neonatal cystitis-induced
chronic visceral pain in rats. Pain
154, 59–70. doi: 10.1016/j.pain.
2012.09.002
Serpente, M., Fenoglio, C., Villa, C.,
Cortini, F., Cantoni, C., Ridolﬁ,
E., et al. (2011). Role of OLR1
and its regulating hsa-miR369-3p
in Alzheimer’s disease: genetics and
expression analysis. J. Alzheimers Dis.
26, 787–793.
Shaked, I., Meerson, A., Wolf,
Y., Avni, R., Greenberg, D.,
Gilboa-Geffen, A., et al. (2009).
MicroRNA-132 potentiates cholin-
ergic anti-inﬂammatory signaling
by targeting acetylcholinesterase.
Immunity 31, 965–973. doi:
10.1016/j.immuni.2009.09.019
Shaltiel, G., Hanan, M., Wolf,
Y., Barbash, S., Kovalev, E.,
Shoham, S., et al. (2013). Hippocam-
pal microRNA-132 mediates stress-
inducible cognitive deﬁcits through
its acetylcholinesterase target. Brain
Struct. Funct. 218, 59–72. doi:
10.1007/s00429-011-0376-z
Smith, L. K., Shah, R. R., and Cidlowski,
J. A. (2010). Glucocorticoids modu-
late microRNA expression and pro-
cessing during lymphocyte apoptosis.
J. Biol. Chem. 285, 36698–36708. doi:
10.1074/jbc.M110.162123
Sommer, C. (2003). Painful neu-
ropathies. Curr. Opin. Neurol. 16,
623–628. doi: 10.1097/00019052-
200310000-00009
Sommer, C., and Kress, M. (2004).
Recent ﬁndings on how proinﬂam-
matory cytokines cause pain: periph-
eral mechanisms in inﬂammatory
and neuropathic hyperalgesia. Neu-
rosci. Lett. 361, 184–187. doi:
10.1016/j.neulet.2003.12.007
Soreq, H., and Wolf, Y. (2011).
NeurimmiRs: microRNAs in the
neuroimmune interface. Trends
Mol. Med. 17, 548–555. doi:
10.1016/j.molmed.2011.06.009
Straube, S., Derry, S., Moore, R. A.,
and McQuay, H. J. (2010). Cervico-
thoracic or lumbar sympathectomy
for neuropathic pain and complex
regional pain syndrome. Cochrane
Database Syst. Rev. CD002918. doi:
10.1002/14651858.CD002918.pub2
Sun, Y., Li, X. Q., Sahbaie, P.,
Shi, X. Y., Li, W. W., Liang, D.
Y., et al. (2012). miR-203 regu-
lates nociceptive sensitization after
incision by controlling phospholi-
paseA2 activating protein expression.
Anesthesiology 117, 626–638. doi:
10.1097/ALN.0b013e31826571aa
Talbot, S., and Couture, R. (2012).
Emerging role of microglial kinin B1
receptor in diabetic pain neuropa-
thy. Exp. Neurol. 234, 373–381. doi:
10.1016/j.expneurol.2011.11.032
Tam Tam, S., Bastian, I., Zhou, X.
F., Vander Hoek, M., Michael, M.
Z., Gibbins, I. L., et al. (2011).
MicroRNA-143 expression in dor-
sal root ganglion neurons. Cell
Tissue Res. 346, 163–173. doi:
10.1007/s00441-011-1263-x
Toyoda, H., Zhao, M. G., and Zhou,
M. (2009). Enhnaced quantal release
of excitatory transmitter in anterior
cingulate cortex of adult mice with
chronic pain. Mol. Pain 5, 4. doi:
10.1186/1744-8069-5–4.
Üceyler, N., Eberle, T., Rolke, R.,
Birklein, F., and Sommer, C. (2007a).
Differential expression patterns of
Frontiers in Molecular Neuroscience www.frontiersin.org October 2013 | Volume 6 | Article 33 | 10
“fnmol-06-00033” — 2013/10/17 — 13:25 — page 11 — #11
Kress et al. ncRNA in pain
cytokines in complex regional pain
syndrome. Pain 132, 195–205. doi:
10.1016/j.pain.2007.07.031
Üceyler, N., Rogausch, J. P., Toyka, K.
V., and Sommer, C. (2007b). Dif-
ferential expression of cytokines
in painful and painless neu-
ropathies. Neurology 69, 42–49. doi:
10.1212/01.wnl.0000265062.92340.a5
Üceyler, N., Göbel, K., Meuth, S.
G., Ortler, S., Stoll, G., Sommer,
C., et al. (2010). Deﬁciency of the
negative immune regulator B7-H1
enhances inﬂammation and neuro-
pathicpain after chronic constric-
tion injury of mouse sciatic nerve.
Exp. Neurol. 222, 153–160. doi:
10.1016/j.expneurol.2009.12.026
Üceyler, N., Schäfers, M., and Som-
mer, C. (2009). Modeof action of
cytokines on nociceptive neurons.
Exp. Brain Res. 196, 67–78. doi:
10.1007/s00221-009-1755-z
van Rooji, E., and Olson, E. N. (2012).
MicroRNA therapeutics for cardio-
vascular disease: opportunities and
obstacles. Nat. Rev. Drug Discov. 11,
860–872. doi: 10.1038/nrd3864
Villa, C., Fenoglio, C., De Riz, M.,
Clerici, F., Marcone, A., Benussi,
L., et al. (2011). Role of hnRNP-A1
and miR-590-3p in neuronal death:
genetics and expression analysis in
patients with Alzheimer disease and
frontotemporal lobar degeneration.
Rejuvenation Res. 14, 275–281. doi:
10.1089/rej.2010.1123
Vincent, A. M., Callaghan, B. C.,
Smith, A. L., and Feldman, E.
L. (2011). Diabetic neuropathy:
cellular mechanisms as therapeu-
tic targets. Nat. Rev. Neurol. 7,
573–583. doi: 10.1038/nrneurol.
2011.137
von Schack, D., Agostino, M. J., Mur-
ray, B. S., Li, Y., Reddy, P. S., Chen,
J., et al. (2011). Dynamic changes
in the microRNA expression pro-
ﬁle reveal mutliple regulatory mech-
anisms in the spinal nerve ligation
model of neuropathic pain. PLoS
ONE 6:e17670. doi: 10.1371/jour-
nal.pone.0017670
Weiland, M., Gao, X. H., Zhou, L., and
Mi, Q. S. (2012). Small RNAs have
a large impact: circulating microR-
NAs as biomarkers for human dis-
eases. RNA Biol. 9, 850–859. doi:
10.4161/rna.20378
Willemen, H. L., Huo, X. J., Mao-Ying,
Q. L., Zijlstra, J., Heijnen, C. J., and
Kavelaars, A. (2012). MicroRNA-124
as a novel treatment for persistent
hyperalgesia. J. Neuroinﬂammation
9, 143. doi: 10.1186/1742-2094-
9–143
Wodarski, R., Clark, A. K., Grist,
J., Marchand, F., and Malcan-
gio, M. (2009). Gabapentin reverses
microglial activation in the spinal
cord of streptozotocin-induced dia-
betic rats. Eur. J. Pain 13, 807–811.
doi: 10.1016/j.ejpain.2008.09.010
Wu, M., Jolicoeur, N., Li, Z., Zhang,
L., Fortin, Y., L’Abbe, D., et al.
(2008). Genetic variations of microR-
NAs in human cancer and their
effects on teh expression of miRNAs.
Carcinogenesis 29, 1710–1716. doi:
10.1093/carcin/bgn073
Wu, Q., Hwang, C. K., Zheng, H.,
Wagley, Y., Lin, H. Y., Kim, D.
K., et al. (2013). MicroRNA 339
down-regulates m-opioid receptor
at the post-transcriptional level in
response to opioid treatment. FASEB
J. 27, 522–535. doi: 10.1096/fj.12-21
3439
Xie, J., Ameres, S. L., Friedline, R.,
Hung, J.-H., Zhang, J., Zhang,Y., et al.
(2012). Long-term, efﬁcient inhibi-
tion of microRNA function in mice
using rAAV vectors. Nat. Methods
9, 403–409. doi: 10.1038/nmeth.
1903
Zeilhofer, H. U., Witschi, R., and Hösl,
K. (2009). Subtype-selective GABAA
receptor mimetics - novel antihy-
peralgesic agents? J. Mol. Med. 87,
465–469. doi: 10.1007/s00109-009-
0454-3
Zhao, J., Lee, M. C., Momin, A., Cen-
dan, C. M., Shepperd, S. T., Baker, M.
D., et al. (2010). Small RNAscontrol
sodium channel expression, noci-
ceptor excitability and pain thresh-
olds. J. Neurosci. 30, 10860–10871.
doi: 10.1523/JNEUROSCI.1980-10.
2010
Zhao, X., Tan, Z., Zhang, H., Atian-
joh, F. E., Zhao, J. Y., Liang,
L., et al. (2013). A long noncod-
ing RNA contributes to neurpathic
pain by silencing Kcna2 in pri-
mary afferent neurons. Nat. Neu-
rosci. 16, 1024–1031. doi: 10.1038/nn.
3438
Conflict of Interest Statement: The
authors declare that the research was
conducted in the absence of any com-
mercial or ﬁnancial relationships that
could be construed as a potential con-
ﬂict of interest.
Received: 05 August 2013; accepted: 24
September 2013; published online: 17
October 2013.
Citation: Kress M,HüttenhoferA, Landry
M, Kuner R, Favereaux A, Greenberg D,
Bednarik J, Heppenstall P, Kronenberg
F, Malcangio M, Rittner H, Üçeyler N,
Trajanoski Z, Mouritzen P, Birklein F,
Sommer C and Soreq H (2013) microR-
NAs in nociceptive circuits as predictors
of future clinical applications. Front.
Mol. Neurosci. 6:33. doi: 10.3389/fnmol.
2013.00033
This article was submitted to the journal
Frontiers in Molecular Neuroscience.
Copyright © 2013 Kress, Hüttenhofer,
Landry, Kuner, Favereaux, Green-
berg, Bednarik, Heppenstall, Kronenberg,
Malcangio, Rittner, Üçeyler, Trajanoski,
Mouritzen, Birklein, Sommer and Soreq.
This is an open-access article distributed
under the terms of the Creative Commons
Attribution License (CC BY). The use,
distribution or reproduction in other
forums is permitted, provided the orig-
inal author(s) or licensor are credited
and that the original publication in
this journal is cited, in accordance with
accepted academic practice. No use,
distribution or reproduction is permit-
ted which does not comply with these
terms.
Frontiers in Molecular Neuroscience www.frontiersin.org October 2013 | Volume 6 | Article 33 | 11
